These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 33596348)

  • 1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Skowronski DM; De Serres G
    N Engl J Med; 2021 Apr; 384(16):1576-1577. PubMed ID: 33596348
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 3. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    Roest S; Hoek RAS; Manintveld OC
    N Engl J Med; 2021 May; 384(20):1968-1970. PubMed ID: 33882226
    [No Abstract]   [Full Text] [Related]  

  • 5. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
    Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
    Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    Barda N; Dagan N; Balicer RD
    N Engl J Med; 2021 May; 384(20):1970. PubMed ID: 33882227
    [No Abstract]   [Full Text] [Related]  

  • 7. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.
    Yanay NB; Freiman S; Shapira M; Wishahi S; Hamze M; Elhaj M; Zaher M; Armaly Z
    Kidney Int; 2021 Jun; 99(6):1496-1498. PubMed ID: 33887318
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders.
    Rosman Y; Lavi N; Meir-Shafrir K; Lachover-Roth I; Cohen-Engler A; Mekori YA; Confino-Cohen R
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3487-3489. PubMed ID: 34224924
    [No Abstract]   [Full Text] [Related]  

  • 9. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.
    Torreggiani M; Blanchi S; Fois A; Fessi H; Piccoli GB
    Kidney Int; 2021 Jun; 99(6):1494-1496. PubMed ID: 33887320
    [No Abstract]   [Full Text] [Related]  

  • 10. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.
    Fernandez-Nieto D; Hammerle J; Fernandez-Escribano M; Moreno-Del Real CM; Garcia-Abellas P; Carretero-Barrio I; Solano-Solares E; de-la-Hoz-Caballer B; Jimenez-Cauhe J; Ortega-Quijano D; Fernandez-Guarino M
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e425-e427. PubMed ID: 33783873
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 12. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2.
    Lesort C; Kanitakis J; Donzier L; Jullien D
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e630-e632. PubMed ID: 34131969
    [No Abstract]   [Full Text] [Related]  

  • 13. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.
    Lombardi A; Bozzi G; Ungaro R; Villa S; Castelli V; Mangioni D; Muscatello A; Gori A; Bandera A
    Front Immunol; 2021; 12():657711. PubMed ID: 33777055
    [No Abstract]   [Full Text] [Related]  

  • 14. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
    Abu-Raddad LJ; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Malek JA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Al Khal A; Butt AA; Bertollini R
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34050372
    [No Abstract]   [Full Text] [Related]  

  • 15. Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient.
    Weinstock-Guttman B; Jakimovski D
    Mult Scler; 2021 Dec; 27(14):2291-2292. PubMed ID: 34100306
    [No Abstract]   [Full Text] [Related]  

  • 16. Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine.
    de Montjoye L; Marot L; Baeck M
    J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e26-e28. PubMed ID: 34547138
    [No Abstract]   [Full Text] [Related]  

  • 17. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G
    J Infect; 2021 Aug; 83(2):e4-e5. PubMed ID: 34214516
    [No Abstract]   [Full Text] [Related]  

  • 18. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC28. PubMed ID: 33646836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?].
    Lanthier L; Carignan A; Plourde MÉ; Cauchon M
    Rev Med Interne; 2021 Mar; 42(3):227-228. PubMed ID: 33612319
    [No Abstract]   [Full Text] [Related]  

  • 20. Skin ulcer at the injection site of BNT162b2 mRNA COVID-19 vaccine.
    Aoki N; Saruta Y; Tanaka S; Nakajima R; Sano H; Sano S
    J Dermatol; 2021 Dec; 48(12):e596-e597. PubMed ID: 34545609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 35.